SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glenmark Pharmaceuticals informs about update

27 Jan 2023 Evaluate

With reference to its letter dated 26th October 2022 informing about the US FDA placing the Baddi (India) facility under import alert 66-40. Glenmark Pharmaceuticals has informed that due to medical necessity and potential drug shortage expectations, the US FDA has provided an exception which enables the Company to supply Atovaquone Oral Suspension USP 750mg/5 to the US market. The exception will be reconsidered if the market conditions change. The Company will engage with the agency to resolve the import alert at the earliest. The Company is committed to maintaining the highest quality and compliant manufacturing standards at all of its facilities across the globe.

The above information is a part of company’s filings submitted to BSE.

Glenmark Pharma Share Price

2364.35 -6.70 (-0.28%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×